Hypoglycemia Pipeline Therapeutic Drugs and Companies Review H1 2015 Research Report

DALLAS, March 16, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Hypoglycemia - Pipeline Review, H1 2015" therapeutic market research report provides an overview of the Hypoglycemia's therapeutic pipeline.

The report Hypoglycemia - Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Hypoglycemia. Hypoglycemia is the clinical syndrome that results from low blood sugar. Hypoglycemia can be caused by drugs taken to control diabetes, fasting, some severe diseases and reactions to carbohydrates, a tumor in the pancreas, and some types of stomach surgery. Each person with diabetes may have different symptoms of hypoglycemia. Signs and symptoms of hypoglycemia includes shakiness, nervousness or anxiety, sweating, chills and clamminess, irritability or impatience, confusion, including delirium, rapid/fast heartbeat, lightheadedness or dizziness, hunger and nausea, sleepiness, blurred/impaired vision, tingling or numbness in the lips or tongue, headaches, weakness or fatigue, anger, stubbornness, or sadness, lack of coordination, nightmares or crying out during sleep, seizures and unconsciousness.

The report "Hypoglycemia - Pipeline Review, H1 2015" is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoglycemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies discussed in this report include:

• Biodel Inc.
• USV Limited
• XERIS Pharmaceuticals, Inc.
• XOMA Corporation
• Zealand Pharma A/S

Drugs profile discussed in this report include: glucagon, glucagon biosimilar, Peptide for Cardiovascular and Hypoglycemia, XOMA-358, ZP-4207.

Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310163 (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: 

• Dec 04, 2014: Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program
• Nov 17, 2014: Zealand advances its proprietary stable glucagon analogue for severe hypoglycemia in diabetes into clinical development
• Nov 12, 2014: FDA and EMA Grant Orphan Designation to Xeris Pharmaceuticals' Soluble Glucagon for Prevention of Hypoglycemia in Congenital Hyperinsulinism Patients
• Jun 17, 2014: Zealand presented new data on ZP-GA-1 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association's (ADA) 74th Scientific Sessions
• Apr 24, 2014: Xeris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation for Pumps
• Oct 17, 2013: Xeris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation
• Jul 03, 2013: Biodel to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference
• Jun 22, 2013: Zealand Pharma Presents Preclinical Data On Hypoglycemic Drug ZP-GA-1 At 73rd ADA Scientific Sessions
• Jun 06, 2013: Biodel Plans To Submit New Drug Application For Glucagon Rescue Product Candidate To Treat Severe Hypoglycemia
• Dec 06, 2012: Biodel's Glucagon Obtains FDA Orphan Drug Designation To Prevent Hypoglycemia In Congenital Hyperinsulinism Population

Scope of this report includes: a snapshot of the global therapeutic landscape of Hypoglycemia; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Hypoglycemia and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Hypoglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Hypoglycemia pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products.

Explore more reports of Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics

Related reports on Dermatology therapeutics:

Type 2 Diabetes - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Type 2 Diabetes. Companies discussed in this report include ActogeniX NV, Addex Therapeutics Ltd, Advinus Therapeutics Ltd., Aegis Therapeutics, LLC, AFFiRiS AG, AlbireoPharma, Alchemia Limited, Alize Pharma SAS, Allozyne, Inc., AlphaMab Co., Ltd, Ambrx, Inc., Amgen Inc., Anchor Therapeutics, Inc., AntriaBio, Inc., Ardelyx, Inc., Arena Pharmaceuticals, Inc., Arisaph Pharmaceuticals, Inc., Array BioPharma Inc., Arrien Pharmaceuticals, LLC, Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, AUS Bio Limited, Avaxia Biologics, Inc., Bayer AG, Betagenon AB, Biocon Limited, Biodel Inc., Biogenomics Limited, BioRestorative Therapies, Inc., BioTherapeutics Inc., Boehringer Ingelheim GmbH, Boston Therapeutics, Inc., Braasch Biotech LLC, Bridge Bioresearch Plc, Bristol-Myers Squibb Company, C4X Discovery Ltd, Cardax Pharmaceuticals, Inc., Cardiolynx AG, Carlina Technologies SAS, Carmot Therapeutics, Inc., Celon Pharma Sp. z o.o., ChemoCentryx, Inc. etc. Complete report available at http://www.rnrmarketresearch.com/type-2-diabetes-pipeline-review-h1-2015-market-report.html

Insulin Resistance - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Insulin Resistance. Companies discussed in this report include AUS Bio Limited, Genfit SA, GlaxoSmithKline plc, Hadasit Medical Research Services & Development Ltd, Mertiva AB, Mochida Pharmaceutical Co., Ltd., Novartis AG, Prometheon Pharma, LLC, Sanofi, Thetis Pharmaceuticals LLC. Complete report available at http://www.rnrmarketresearch.com/insulin-resistance-pipeline-review-h1-2015-market-report.html

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:

G+ / Google Plus:https://plus.google.com/u/0/104156468549256253075/

Twitter:https://twitter.com/RnRMR

Facebook:https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds:http://www.rnrmarketresearch.com/feed

Contact:  

Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected] 

SOURCE RnR Market Research